Nearly one third of patients with advanced melanoma saw tumors disappear completely after receiving TIL therapy plus pembrolizumab immunotherapy

https://www.news-medical.net/news/20261024/Nearly-one-third-of-patients-with-advanced-melanoma-saw-tumors-disappear-completely-after-receiving-TIL-therapy-plus-pembrolizumab-immunotherapy.aspx Results from a clinical trial have revealed nearly one third (29.2 percent) of patients with advanced melanoma saw their tumors disappear completely on scans after receiving lifileucel TIL therapy alongside an immune checkpoint inhibitor, pembrolizumab, as a first-line treatment. In addition, approximately two thirds (62.5 percent) of patients in the same group saw their tumors shrink significantly, with many experiencing substantial and long-lasting responses to the combined treatment.